Cetuximab.
Goldberg, Richard M
Nature reviews. Drug discovery, Suppl: S10-1 (2005)
2004
Kivonat megmutatása
Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the US FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II trials. | 15962524
 |
Epidermal growth factor inhibition in solid tumours.
Ganti, Apar Kishor and Potti, Anil
Expert opinion on biological therapy, 5: 1165-74 (2005)
2004
Kivonat megmutatása
The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned. | 16120047
|
